Cargando…

A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality

Introduction: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akgun, Zuleyha, Cakir, Aydin, Sağlam, Esra, Demirel, Sertac, Igci, Abdullah, Keskin, Serkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144295/ https://www.ncbi.nlm.nih.gov/pubmed/37109633 http://dx.doi.org/10.3390/medicina59040675

Ejemplares similares

Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study
por: Yadav, Budhi Singh, et al.
Publicado: (2022)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Feasibility and Outcomes of Hypofractionated Simultaneous Integrated Boost-Intensity Modulated Radiotherapy for Malignant Gliomas: A Preliminary Report
por: Cha, Jihye, et al.
Publicado: (2014)

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation
por: Cante, Domenico, et al.
Publicado: (2020)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
por: Krug, David, et al.
Publicado: (2020)

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review
por: Schmitt, Martin, et al.
Publicado: (2022)

Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
por: Montero, Angel, et al.
Publicado: (2023)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
por: Jiang, Huayong, et al.
Publicado: (2021)

Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis
por: Dong, Jinling, et al.
Publicado: (2021)

Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2018)

Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer
por: Jain, Neeraj, et al.
Publicado: (2022)

Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound
por: Landoni, Valeria, et al.
Publicado: (2013)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost
por: van Schie, Marcel A., et al.
Publicado: (2019)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
por: Zhong, Liangzhi, et al.
Publicado: (2019)

Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
por: Di Muzio, Nadia Gisella, et al.
Publicado: (2021)

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
por: Jorgo, Kliton, et al.
Publicado: (2019)

Successful treatment of triple primary tumor()()
por: Kurul, Sidika, et al.
Publicado: (2013)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes
por: Gadea, J., et al.
Publicado: (2021)

Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity
por: Deantonio, Letizia, et al.
Publicado: (2010)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Cost Minimization Analysis of Hypofractionated Radiotherapy
por: Yaremko, Hannah L., et al.
Publicado: (2021)

Hypofractionated Radiotherapy in African Cancer Centers
por: Swanson, William, et al.
Publicado: (2021)

A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects
por: Guenzi, Marina, et al.
Publicado: (2010)

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity
por: Chitapanarux, Imjai, et al.
Publicado: (2019)

Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis
por: Jacobs, Corbin D., et al.
Publicado: (2019)

Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2022)

Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials
por: Pfaffendorf, Charlotte, et al.
Publicado: (2022)

Comparing Outcomes of Oligometastases Treated with Hypofractionated Image-Guided Radiotherapy (HIGRT) with a Simultaneous Integrated Boost (SIB) Technique versus Metastasis Alone: A Multi-Institutional Analysis
por: Shenker, Rachel F., et al.
Publicado: (2022)

Technical Note: Break‐even dose level for hypofractionated treatment schedules
por: Böhlen, Till Tobias, et al.
Publicado: (2021)

Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy
por: Cui, Ming, et al.
Publicado: (2022)

Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma
por: Tao, Chang-Juan, et al.
Publicado: (2013)

Dosimetric comparison of standard three-dimensional conformal radiotherapy followed by intensity-modulated radiotherapy boost schedule (sequential IMRT plan) with simultaneous integrated boost–IMRT (SIB IMRT) treatment plan in patients with localized carcinoma prostate
por: Bansal, A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qjqh9aff7hgm3hbioqaj6f7g82